Akcea therapeutics share price

BOSTON , March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , announced today that its board of directors has appointed Damien McDevitt , Ph.D. as Chief Executive Officer, effective immediately. Akcea Therapeutics | Crunchbase Oct 04, 2017 · Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is a development and commercialization company focused on transforming serious cardiometabolic lipid disorders. Akcea's portfolio spans multiple targets and disease states, including both rare and more common lipid disorders, using advanced RNA-targeted antisense therapeutics.

Akcea Therapeutics, Inc. - AKCA - Stock Price & News | The ... Real time Akcea Therapeutics, Inc. (AKCA) stock price quote, stock graph, news & analysis. Home - Akcea Therapeutics Our Commitment At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to … AKCA | Akcea Therapeutics Inc. Profile | MarketWatch Nov 01, 2019 · Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare … AKCA Stock Price, Forecast & News (Akcea Therapeutics)

Akcea Therapeutics, Inc. We will share the initial WAYLIVRA price when we launch and we expect to be in the typical rare disease price range. We ended Q2 with $296 million in cash and short

AKCA: Akcea Therapeutics Inc - Stock Price, Quote ... - CNBC Get Akcea Therapeutics Inc (AKCA:NASDAQ) real-time stock quotes, news and financial information from CNBC. Share Your Chart. Pipeline - Akcea Therapeutics AKCEA-TTR-L Rx for the treatment of ATTR. We are co-developing AKCEA-TTR- L Rx with Ionis Pharmaceuticals to inhibit the production of transthyretin (TTR). We plan to develop AKCEA-TTR-L Rx for patients with both the hereditary and the wild-type forms of ATTR. AKCEA-TTR- L Rx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) technology platform and is AKCA Stock | AKCEA THERAPEUTICS Stock Price Today ...

AKCA Akcea Therapeutics, Inc. Stock Quote

Real time Akcea Therapeutics, Inc. (AKCA) stock price quote, stock graph, news & analysis. Home - Akcea Therapeutics

Akcea Therapeutics, Inc. Common Stock (AKCA) Real-Time ...

Pipeline - Akcea Therapeutics AKCEA-TTR-L Rx for the treatment of ATTR. We are co-developing AKCEA-TTR- L Rx with Ionis Pharmaceuticals to inhibit the production of transthyretin (TTR). We plan to develop AKCEA-TTR-L Rx for patients with both the hereditary and the wild-type forms of ATTR. AKCEA-TTR- L Rx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) technology platform and is AKCA Stock | AKCEA THERAPEUTICS Stock Price Today ... AKCA: Get the latest Akcea Therapeutics stock price and detailed information including AKCA news, historical charts and realtime prices.

Akcea Therapeutics has a market capitalization of $1.45 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. View additional information about Akcea Therapeutics.

Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Call ... Akcea Therapeutics, Inc. We will share the initial WAYLIVRA price when we launch and we expect to be in the typical rare disease price range. We ended Q2 with $296 million in cash and short Akcea Therapeutics Announces Closing of Initial Public ... Jul 19, 2017 · CAMBRIDGE, Mass., July 19, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the closing of its initial public offering of 17,968,750 shares common stock at a public offering price of $8.00 per share, including 2,343,750 shares of common stock issued upon full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the offering … Akcea Therapeutics Inc., AKCA Quick Chart - (NAS) AKCA ... Akcea, Ionis shares halted premarket for news pending MarketWatch. Friday, March 16, 2018. 08:13 AM ET. Akcea Therapeutics price target raised to $30 from $30 at Stifel MarketWatch. Tuesday, February 27, 2018. 07:33 AM ET. Akcea Therapeutics downgraded to …

AKCA Stock Price and Chart — NASDAQ:AKCA — TradingView Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. Akcea Therapeutics Establishes Canadian Subsidiary Nasdaq:AKCA Sep 06, 2017 · Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic Akcea Therapeutics Stock Price History + Charts (AKCA ...